Cancer clinical research scholars move discoveries from lab to patients

Five oncologists at Oregon Health & Science University in Portland will receive a $25,000 salary supplement for one year, allowing them to reserve time to pursue promising research ideas.


Uma Borate, M.D., M.S.

Michael Heinrich, M.D., professor in the division of hematology and medical oncology at the OHSU Knight Cancer Institute; physician at the Portland Veterans Affairs Medical Center, November 1, 2017. (OHSU/Kristyna Wentz-Graff)

Michael Heinrich, M.D.

Taylor_Matthew_10 (1)

Matthew Taylor, M.D.

Vaccaro, Gina

Gina Vaccaro, M.D.

Vuky, Jacqueline

Jacqueline Vuky, M.D.

The Knight Cancer Institute’s Clinical Research Scholar Awards aim to help physician-scientists advance discoveries with the greatest potential to improve cancer therapy, early diagnosis or prevention.

Read more…

What magnitude of benefit is meaningful to cancer patients?

Oncologists often use the phrase “clinically meaningful benefit” to describe the effect of an experimental treatment. But is the benefit meaningful for patients? A new paper suggests that benefit claims in journal articles often fall short.


benefit figure

Gains in median overall survival, in months, deemed “clinically meaningful” (Dreicer et al.)

Read more…

Cancer translated’s top blog posts of 2017

year end collage (1)

From basic science to survivorship and patient advocacy, the OHSU Knight Cancer Institute’s ‘Cancer translated’ blog explores new ideas and debates in cancer medicine. We sorted a year’s worth of posts to find the most heavily trafficked reports. Here are the top 10 in order of popularity:

Read more…

NCI-funded project aims to increase HPV vaccine coverage in rural Oregon

HPV vaccination map detail

HPV vaccination coverage in Oregon varies by county. Numbers in this map show the rate of three-dose completion for teen girls and boys combined.

A safe and effective vaccine to prevent cancers caused by human papillomavirus became available more than 10 years ago, yet today less than half of Oregon teenagers complete the series of shots recommended for 13- to 17-year-olds. And that coverage looks even worse when examined by geography. Rates of completed vaccination in rural Oregon counties were as low as 16 percent for teen girls and 6 percent for teen boys as of May 2016.

OHSU researchers are aiming to improve HPV vaccination rates by exploring the unique reasons for high and low uptake in adjacent rural areas. “We want to understand both the barriers to vaccination and also the factors that may be informing and driving the successes,” says project leader Jackie Shannon, Ph.D., a professor in the OHSU-PSU School of Public Health and the Knight Cancer Institute’s director of community engaged research.

Read more…

Knight Cancer Institute signal achievements of 2017

Serving Oregonians. Delivering discoveries. Developing talented clinicians and scientists. Leading the way. Here’s a look back at accomplishments by the staff and faculty of the Knight Cancer Institute. They reflect a mission of delivering compassionate care and scientific discoveries that will end cancer as we know it.

Anupriya Agarwal, Ph.D., works in her lab (OHSU/Kristyna Wentz-Graff)(OHSU/Kristyna Wentz-Graff)

Read more…

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay resistance to cancer therapies, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt.

drug resistance diagram

Read more…

Check out the Knight Cancer pilot project award winners

Preventing skin cancer with a DNA-repair enzyme. Using zebrafish embryos to rapidly assess toxicity of anticancer drug combinations. Understanding how microRNAs modify cancer immunity. These are some of the ideas researchers are pursuing with the latest round of Knight Cancer Institute pilot project grants.

Read more…

How strength training may improve cancer survival

Cancer survivors who engage in strength training or other vigorous physical activity tend to live longer and have a lower risk of recurrence than those who don’t work out. A new study helps explain why.

2017_1116_exercisevideo_006 (1)

Read more…

How to retarget cancers that have evaded targeted therapy

Michael Heinrich, M.D. meets with Victoria Castle of Sacramento, California during an appointment, November 1, 2017 at OHSU. Castle, who was diagnosed with gastrointestinal stromal tumor in 2009, began seeing Heinrich in 2014. (OHSU/Kristyna Wentz-Graff)

Michael Heinrich, M.D., meets with Victoria Castle of Sacramento, California, who was diagnosed with gastrointestinal stromal tumor in 2009. Her cancer became resistant to existing drugs, and she enrolled in a clinical trial of BLU-285, a targeted therapy agent designed to overcome resistance. (OHSU/Kristyna Wentz-Graff)

Targeted therapy drugs transformed the outlook for people with the rare cancers known as gastrointestinal stromal tumors, enabling some to survive a decade or longer. A fraction of GIST patients, however, never respond to treatment. And most of those who do respond eventually relapse because cancer cells evolve and become resistant to the drugs designed to stop them. It’s the big limitation of targeted therapies.

But researchers now have found a way to retarget GISTs that have evaded targeted therapy. The new agent is being tested in a phase 1 clinical trial at OHSU and other medical centers, and the company developing it has announced plans to begin a phase 3 trial in the first half of 2018.

“We have seen many patients with a good response to treatment, even after many failed prior treatment attempts with conventional drugs,” said Michael Heinrich, M.D., an OHSU Knight Cancer Institute scientist and VA Portland Health System oncologist. “Some of the lesions disappear. It’s really quite dramatic.”

Read more…

Clearing the quandary of cancer early detection

For many cancers, five-year survival rates approach 99 percent if the disease is detected early, when tumors are small and not yet spreading.

But efforts to detect cancers early have led to a quandary. Current screening tests too often fail to find high-risk cancers while at the same time raising too many alarms about essentially harmless growths. The technologies used for early detection can’t reliably distinguish aggressive, life-threatening abnormalities from those that are unlikely to ever become dangerous.


Marquam Hill Lecture: The promise of early cancer detection

Sadik Esener, Ph.D.
Thursday, Nov. 16, 2017 at 7 p.m.
OHSU Auditorium
Register to attend

At the OHSU Knight Cancer Institute, Sadik Esener, Ph.D., is building a multidisciplinary team seeking to overcome this dilemma. In a Marquam Hill Lecture in November, he’ll explain how Knight Cancer Institute scientists are probing cancer’s initiating events and early malignant changes, and applying this knowledge to develop low-cost screening tests, determine which cancers to vigorously treat, and direct precision therapies to minimize toxicity.

Esener is the Wendt Family Chair professor of biomedical engineering in the OHSU School of Medicine and director of CEDAR, the Knight Cancer Institute’s Early Detection Advanced Research Center.

Solving the problem of drug-resistant cancer

Solving the problem of drug-resistant cancer

To discover ways to prevent or delay drug resistance in cancer, a new NCI-funded center at OHSU is exploring how acute myeloid leukemia cells evolve and adapt.